ライフサイエンスコーパス: diffuse large B-cell lymphoma

1 for patients with relapsed and/or refractory diffuse large B cell lymphoma.

2 op an aggressive malignancy resembling human diffuse large B cell lymphoma.

3 II expression in germinal center B cells and diffuse large B cell lymphoma.

4 fore allogeneic stem cell transplantation in diffuse large B-cell lymphoma.

5 (del17p or del11q), follicular lymphoma, or diffuse large B-cell lymphoma.

6 mphocytic lymphoma, follicular lymphoma, and diffuse large B-cell lymphoma.

7 oblastic leukemia, plasma cell neoplasms, or diffuse large B-cell lymphoma.

8 (EFS24) is a clinically useful end point in diffuse large B-cell lymphoma.

9 notherapy in untreated elderly patients with diffuse large B-cell lymphoma.

10 issues when treating patients with high-risk diffuse large B-cell lymphoma.

11 a quarter of Burkitt lymphoma and GC-derived diffuse large B-cell lymphoma.

12 ecially for those with aggressive forms like diffuse large B-cell lymphoma.

13 able to transform into germinal center-type diffuse large B-cell lymphoma.

14 nd death and exhibit many mutations found in diffuse large B-cell lymphoma.

15 ely disappointing in follicular lymphoma and diffuse large B-cell lymphoma.

16 primary refractory (rel/ref) chemorefractory diffuse large B-cell lymphoma.

17 (CHP) in patients with previously untreated diffuse large B-cell lymphoma.

18 , primarily acute lymphoblastic leukemia and diffuse large B-cell lymphoma.

19 ion with rituximab in relapsed or refractory diffuse large B-cell lymphoma.

20 prednisone (R-CHOP) as frontline therapy for diffuse large B-cell lymphoma.

21 prove the outcome of high-risk patients with diffuse large B-cell lymphomas.

22 a combination therapy that frequently cures Diffuse Large B-Cell Lymphomas.

23 and thyroid (0.68) and for melanoma (0.83), diffuse large B-cell lymphoma (0.89), and follicular lym

24 ix patients with heavily pretreated relapsed diffuse large B-cell lymphoma (3 men, 3 women; aged, 54

25 st common mature noncutaneous lymphomas were diffuse large B-cell lymphomas (32.4%), follicular lymph

26 remission occurred in 6 of 14 patients with diffuse large B-cell lymphoma (43%; 95% CI, 18 to 71) an

27 For diffuse large B-cell lymphoma, 5-year net survival in no

28 3 patients were enrolled and treated; 19 had diffuse large B-cell lymphoma, 53 follicular lymphoma, a

29 oma, 67% in mantle cell lymphoma, and 30% in diffuse large B-cell lymphoma; 93% of responses occurred

30 ctory cancers, such as activated B cell-like diffuse large B cell lymphoma (ABC DLBCL), are likely re

31 t lower GRK2 levels in activated B cell-type diffuse large B cell lymphoma (ABC-DLBCL) are associated

32 Activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL) is an aggressi

33 Three patients with diffuse large B-cell lymphoma achieved durable objective

34 A node and gastric biopsy confirmed diffuse large-B-cell lymphoma, activated B cell type, wi

35 years or older with pathologically confirmed diffuse large B-cell lymphoma, an Eastern Cooperative On

36 ortant in several human malignancies such as diffuse large B cell lymphoma and chronic lymphocytic le

37 Additionally, BCL-W was overexpressed in diffuse large B cell lymphoma and correlated with decrea

38 ons drive constitutive NF-kappaB activity in diffuse large B cell lymphoma and other lymphoid cancers

39 features vs 20 patients with HIV-associated diffuse large B-cell lymphoma and 19 patients with sympt

40 81 patients with diffuse large B-cell lymphoma and 41 patients with folli

41 81 patients with diffuse large B-cell lymphoma and 42 with follicular lym

42 cytic leukemia, 29% of activated B-cell type diffuse large B-cell lymphoma and 90% of Waldenstrom mac

43 uently in follicular lymphoma and aggressive diffuse large B-cell lymphoma and are associated with H3

44 etter outcomes for patients with early stage diffuse large B-cell lymphoma and follicular lymphoma su

45 ions in patients with relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma.

46 e in the treatment of relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma.

47 ina) in patients with relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma.

48 Diffuse large B-cell lymphoma and MCL had a poor prognos

49 The aim of treatment of diffuse large B-cell lymphoma and peripheral T-cell lymp

50 consolidation radiotherapy in patients with diffuse large B-cell lymphoma and primary mediastinal B-

51 Application of our tool on diffuse large B-cell lymphoma and prostate cancer demons

52 ld be detected in the serum of patients with diffuse large-B-cell lymphoma and used to predict clinic

53 cular lymphoma, 16 (36%) of 45 patients with diffuse large B-cell lymphoma, and 13 (65%) of 20 patien

54 , an enhanced expression was observed in HL, diffuse large B-cell lymphoma, and lymphoblastoid cell l

55 acetylation signature in the ABC subgroup of diffuse large B-cell lymphoma, and one of the most frequ

56 oma (del17p or del11q), follicular lymphoma, diffuse large B-cell lymphoma, and Richter's transformat

57 ymphomas, including mantle cell lymphoma and diffuse large B-cell lymphoma, and supports constitutive

58 king, including follicular lymphoma and most diffuse large B-cell lymphomas, anti-PD-1 therapy has be

59 nversely, the D2HGDH mutants that we find in diffuse large B-cell lymphoma are enzymatically inert.

60 Diffuse large B-cell lymphoma arising in immune-privileg

61 ic active B-cell receptor (BCR) signaling in diffuse large B-cell lymphoma as a model system to estab

62 Remarkably, diffuse large B cell lymphoma-associated gain-of-functio

63 or T-cell (CAR-T) therapies are approved for diffuse large B-cell lymphoma, axicabtagene ciloleucel (

64 In germinal center diffuse large B-cell lymphoma, BCL-2 levels or venetocla

65 erapy has substantially reduced the risks of diffuse large B-cell lymphoma, Burkitt lymphoma, and pri

66 chemotherapy in older patients with advanced diffuse large B-cell lymphoma, but further comparative s

67 chemotherapy in older patients with advanced diffuse large B-cell lymphoma, but further comparative s

68 Biologically distinct subtypes of diffuse large B-cell lymphoma can be identified using ge

69 Loss of FBXW7 inhibited diffuse large B-cell lymphoma cell growth and further se

70 optosis and cell cycle arrest in Burkitt and diffuse large B-cell lymphoma cell lines, which are mode

71 re, RNF181 limits the proliferation of human diffuse large B cell lymphoma cells that depend upon abe

72 normal B cells as well as different types of diffuse large B cell lymphoma cells.

73 ized B-cell acute lymphoblastic leukemia and diffuse large B-cell lymphoma cells to anti-CD19 CAR T c

74 bind B cells and high-grade B cell lymphoma (diffuse large B cell lymphoma) cells.

75 1.5 months (IQR 16.7-24.3) for the untreated diffuse large B-cell lymphoma cohort treated at the pola

76 In the diffuse large B-cell lymphoma cohort, grade 3-5 adverse

77 emia) was reported at the 420 mg dose in the diffuse large B-cell lymphoma cohort, which resolved aft

78 Primary lymphoma of the CNS (PCNSL) is a diffuse large B cell lymphoma confined to the CNS.

79 among the most common genetic alterations in diffuse large B cell lymphoma (DLBCL) and follicular lym

80 on mutations that are frequently observed in diffuse large B cell lymphoma (DLBCL) and that disrupt I

81 ogenic BCL6 and EZH2 cooperate to accelerate diffuse large B cell lymphoma (DLBCL) development and co

82 of CD37 on neoplastic cells in patients with diffuse large B cell lymphoma (DLBCL) directly correlate

83 Sequencing studies of diffuse large B cell lymphoma (DLBCL) have identified hu

84 Diffuse large B cell lymphoma (DLBCL) is a highly hetero

85 lopment of precision medicine approaches for diffuse large B cell lymphoma (DLBCL) is confounded by i

86 Diffuse large B cell lymphoma (DLBCL) is the most common

87 oyment of rationally developed therapies for diffuse large B cell lymphoma (DLBCL) requires rapid ass

88 ositive association of total TFA levels with diffuse large B cell lymphoma (DLBCL) risk [n = 98 cases

89 f the activated B cell-like (ABC) subtype of diffuse large B cell lymphoma (DLBCL), engages the CARD1

90 Diffuse large B cell lymphoma (DLBCL), the most common s

91 To repurpose compounds for diffuse large B cell lymphoma (DLBCL), we screened a lib

92 265P), CD79B mutant (MCD) genetic subtype of diffuse large B cell lymphoma (DLBCL), which relies on B

93 compared it with that of the more aggressive Diffuse Large B Cell Lymphoma (DLBCL).

94 germinal center (GC) B cell-like subtypes of diffuse large B cell lymphoma (DLBCL).

95 ly overlaps with that in the closely related diffuse large B cell lymphoma (DLBCL).

96 ansplant recipients have heightened risk for diffuse large B cell lymphoma (DLBCL).

97 port integrative genetic characterization of diffuse large B cell lymphomas (DLBCL), including large-

98 ng activity against recurrent and refractory diffuse large B cell lymphomas (DLBCL).

99 ]), follicular lymphoma (FL) (23% [n = 20]), diffuse large B-cell lymphoma (DLBCL) (10% [n = 9]), man

100 frequent subtype (57%, n = 452), followed by diffuse large B-cell lymphoma (DLBCL) (15%, n = 118), fo

101 cell lymphoma (MCL) (6.8% [18 of 263]), and diffuse large B-cell lymphoma (DLBCL) (4.6% [12 of 263).

102 8%), follicular lymphoma (FL) (n = 26, 10%), diffuse large B-cell lymphoma (DLBCL) (n = 25, 10%), and

103 Few patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) achieve prolonged

104 The PI3K-mTORC pathway is upregulated in diffuse large B-cell lymphoma (DLBCL) and can be targete

105 ing of the pathogenesis and heterogeneity of diffuse large B-cell lymphoma (DLBCL) and follicular lym

106 The standardized incidence ratios (SIRs) of diffuse large B-cell lymphoma (DLBCL) and follicular lym

107 ated T cells (NFAT) signaling in subtypes of diffuse large B-cell lymphoma (DLBCL) and identify a pot

108 We analyze human diffuse large B-cell lymphoma (DLBCL) and non-DLBCL path

109 atment options for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) are limited, with

110 e-expressor lymphomas (DELs) are subtypes of diffuse large B-cell lymphoma (DLBCL) associated with po

111 immunochemotherapy after 2 cycles (PET-2) in diffuse large B-cell lymphoma (DLBCL) by applying 2 diff

112 uno-chemotherapy after two cycles (PET-2) in diffuse large B-cell lymphoma (DLBCL) by applying two di

113 shRNA knockdown showed that almost all diffuse large B-cell lymphoma (DLBCL) cell lines are add

114 a subset of non-germinal center B-cell (GCB) diffuse large B-cell lymphoma (DLBCL) cell lines, charac

115 scription factor (ATF) family in survival of diffuse large B-cell lymphoma (DLBCL) cells.

116 ative genomic and transcriptomic analysis of diffuse large B-cell lymphoma (DLBCL) from the British C

117 Distinct subgroups of diffuse large B-cell lymphoma (DLBCL) genetically resemb

118 Diffuse large B-cell lymphoma (DLBCL) has been categoriz

119 -guided treatment decisions in patients with diffuse large B-cell lymphoma (DLBCL) has been the subje

120 Therapeutic advances for diffuse large B-cell lymphoma (DLBCL) have led to an inc

121 ttempts to redefine R-CHOP for patients with diffuse large B-cell lymphoma (DLBCL) have migrated from

122 er latency to the development of BCL6-driven diffuse large B-cell lymphoma (DLBCL) in a murine model.

123 Routine imaging for diffuse large B-cell lymphoma (DLBCL) in first complete

124 urpose The general outlook for patients with diffuse large B-cell lymphoma (DLBCL) in first remission

125 hisms (SNPs) at four susceptibility loci for diffuse large B-cell lymphoma (DLBCL) in individuals of

126 Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous

127 Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous

128 r personalized targeted treatment.IMPORTANCE Diffuse large B-cell lymphoma (DLBCL) is a highly aggres

129 Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is an aggressive c

130 Diffuse large B-cell lymphoma (DLBCL) is an aggressive d

131 Diffuse large B-cell lymphoma (DLBCL) is an aggressive l

132 outcome of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) is poor, particula

133 pose The standard treatment of patients with diffuse large B-cell lymphoma (DLBCL) is rituximab in co

134 Diffuse large B-cell lymphoma (DLBCL) is the most common

135 Diffuse large B-cell lymphoma (DLBCL) is the most common

136 Diffuse large B-cell lymphoma (DLBCL) may present initia

137 h BCL2 rearrangements (HGBL-DH/TH- BCL2) and diffuse large B-cell lymphoma (DLBCL) morphology through

138 Patients with relapsed diffuse large B-cell lymphoma (DLBCL) not eligible for a

139 A hallmark of the diffuse large B-cell lymphoma (DLBCL) of the activated B

140 Primary diffuse large B-cell lymphoma (DLBCL) of the ocular regi

141 Refractory or relapsed diffuse large B-cell lymphoma (DLBCL) often associates w

142 Early identification of ultra-risk diffuse large B-cell lymphoma (DLBCL) patients is needed

143 ons occurring in tumor samples from selected diffuse large B-cell lymphoma (DLBCL) patients, 2 recent

144 survival (PFS) and overall survival (OS) in diffuse large B-cell lymphoma (DLBCL) patients.

145 Some patients with diffuse large B-cell lymphoma (DLBCL) present with a con

146 Diffuse large B-cell lymphoma (DLBCL) presents as a limi

147 phoma patients, transformation to aggressive diffuse large B-cell lymphoma (DLBCL) reduces median sur

148 The activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) relies on chronic

149 apy (RT) after chemotherapy in limited-stage diffuse large B-cell lymphoma (DLBCL) remains controvers

150 However, the role of BCR blockade in diffuse large B-cell lymphoma (DLBCL) remains undefined.

151 l-like (ABC) and germinal center B-cell-like diffuse large B-cell lymphoma (DLBCL) represent the 2 ma

152 Diffuse large B-cell lymphoma (DLBCL) represents the mos

153 We show that ATM deficiency in diffuse large B-cell lymphoma (DLBCL) significantly indu

154 uishes the aggressive activated B cell (ABC) diffuse large B-cell lymphoma (DLBCL) subtype from the b

155 The clinical features of diffuse large B-cell lymphoma (DLBCL) subtype of ocular

156 side various clinical prognostic factors for diffuse large B-cell lymphoma (DLBCL) such as the intern

157 The majority of diffuse large B-cell lymphoma (DLBCL) tumors contain mut

158 Patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) underwent both FLT

159 lity therapy for patients with limited-stage diffuse large B-cell lymphoma (DLBCL) was shown in the S

160 baseline studies, is a prognostic factor in diffuse large B-cell lymphoma (DLBCL) whose measurement

161 ies centered on follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) within the context

162 mor stasis in an activated B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL) xenograft model, b

163 iR-28 reexpression in human Burkitt (BL) and diffuse large B-cell lymphoma (DLBCL) xenografts blocked

164 ns are ubiquitous in cHL, they also occur in diffuse large B-cell lymphoma (DLBCL), albeit with a low

165 evaluated in neuroblastoma, medulloblastoma, diffuse large B-cell lymphoma (DLBCL), and EOC microarra

166 including Burkitt lymphoma, Hodgkin disease, diffuse large B-cell lymphoma (DLBCL), and posttransplan

167 Biologic heterogeneity is a feature of diffuse large B-cell lymphoma (DLBCL), and the existence

168 cance of MYC and BCL2 genetic alterations in diffuse large B-cell lymphoma (DLBCL), apart from transl

169 In patients with diffuse large B-cell lymphoma (DLBCL), most relapses occ

170 In diffuse large B-cell lymphoma (DLBCL), the number of cir

171 ient mouse model that spontaneously develops diffuse large B-cell lymphoma (DLBCL).

172 imited for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

173 randomized clinical trials of patients with diffuse large B-cell lymphoma (DLBCL).

174 th non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma (DLBCL).

175 ll receptor (BCR) signaling in cell lines of diffuse large B-cell lymphoma (DLBCL).

176 ttle is known of the role of this pathway in diffuse large B-cell lymphoma (DLBCL).

177 ng mutations in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL).

178 tion in the treatment of mutant MYD88(L265P) diffuse large B-cell lymphoma (DLBCL).

179 , are frequently over-expressed in high-risk diffuse large B-cell lymphoma (DLBCL).

180 tuximab exposure on outcome in patients with diffuse large B-cell lymphoma (DLBCL).

181 (MYC) and B-cell lymphoma gene-2 (BCL2), in diffuse large B-cell lymphoma (DLBCL).

182 nt of tumors from diverse origins, including diffuse large B-cell lymphoma (DLBCL).

183 ly increases the inhibitor's cytotoxicity in diffuse large B-cell lymphoma (DLBCL).

184 etermination of prognosis after treatment of diffuse large B-cell lymphoma (DLBCL).

185 atment purposes is increasingly impelling in diffuse large B-cell lymphoma (DLBCL).

186 pathobiology of several neoplasms including diffuse large B-cell lymphoma (DLBCL).

187 val exists for patients newly diagnosed with diffuse large B-cell lymphoma (DLBCL).

188 rous distinct B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL).

189 ofiling has identified 2 major subclasses of diffuse large B-cell lymphoma (DLBCL).

190 protein Galpha13, in Burkitt's lymphoma and diffuse large B-cell lymphoma (DLBCL).

191 box protein 1 (FOXP1) is a common feature of diffuse large B-cell lymphoma (DLBCL).

192 alignancies including activated B-cell (ABC) diffuse large B-cell lymphoma (DLBCL).

193 t Hodgkin lymphoma (NLPHL) to transform into diffuse large B-cell lymphoma (DLBCL).

194 address persistent unmet clinical needs for diffuse large B-cell lymphoma (DLBCL).

195 try (IHC) is associated with poor outcome in diffuse large B-cell lymphoma (DLBCL).

196 mutations are recurrently detected in human diffuse large B-cell lymphoma (DLBCL).

197 as a therapeutic target for the treatment of diffuse large B-cell lymphoma (DLBCL).

198 promising biomarker of pretreatment risk in diffuse large B-cell lymphoma (DLBCL).

199 as become standard of care for patients with diffuse large B-cell lymphoma (DLBCL).

200 eukemia (CLL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL).

201 ates with inferior survival in patients with diffuse large B-cell lymphoma (DLBCL).

202 lled, most with follicular lymphoma (43%) or diffuse large B-cell lymphoma (DLBCL; 32%).

203 ; n = 28), follicular lymphoma (FL; n = 29), diffuse large B-cell lymphoma (DLBCL; n = 34), DLBCL ari

204 In 86 evaluable patients with diffuse large B-cell lymphoma (DLBCL; n = 61), plasmabla

205 es occurred in the subgroup of patients with diffuse large B-cell lymphoma (DLBCL; n=9), and three oc

206 effective in providing a sc-COO for ~80% of diffuse large B cell lymphomas (DLBCLs) and identified n

207 Diffuse large B cell lymphomas (DLBCLs) are genetically

208 Diffuse large B cell lymphomas (DLBCLs) arise from proli

209 Here we demonstrate that diffuse large B cell lymphomas (DLBCLs) expressing LMO2

210 , we employed genome-wide screening in human diffuse large B cell lymphomas (DLBCLs).

211 ement (MYC-R) occurs in approximately 10% of diffuse large B-cell lymphomas (DLBCLs) and has been ass

212 tify HGBL-DH and will reclassify a subset of diffuse large B-cell lymphomas (DLBCLs) and HGBLs with f

213 Activated B-cell (ABC)-diffuse large B-cell lymphomas (DLBCLs) are clinically a

214 Diffuse large B-cell lymphomas (DLBCLs) contain 2 major

215 Epstein-Barr virus-positive (EBV+) diffuse large B-cell lymphomas (DLBCLs) express high lev

216 Aggressive double- and triple-hit (DH/TH) diffuse large B-cell lymphomas (DLBCLs) feature activati

217 tonic B-cell receptor (BCR) signal-dependent diffuse large B-cell lymphomas (DLBCLs) inhibits cellula

218 rrangements (HGBL-DH/THs) include a group of diffuse large B-cell lymphomas (DLBCLs) with inferior ou

219 terminal hydrolase L1 (UCH-L1) is induced in diffuse large B-cell lymphomas (DLBCLs), and that levels

220 previously reported that early-stage gastric diffuse large B-cell lymphomas (DLBCLs), including DLBCL

221 In diffuse large B-cell lymphomas (DLBCLs), JAK signaling i

222 eat the HCV-positive patients suffering from diffuse large B-cell lymphomas (DLBCLs).

223 the study: eight with relapsed or refractory diffuse large B-cell lymphoma (due to progressive diseas

224 In diffuse large B-cell lymphoma, early assessment of treat

225 glucose ((18)F-FDG) PET in the assessment of diffuse large B-cell lymphoma, follicular lymphoma, and

226 in adult patients with non-Hodgkin lymphoma (diffuse large B-cell lymphoma, follicular lymphoma, mant

227 day), and six additional patients (two with diffuse large B-cell lymphoma, four with indolent lympho

228 ucel in multiply relapsed/refractory, adult, diffuse large B-cell lymphoma from a US health payer per

229 ently mutated in germinal-centre B cell-like diffuse large B cell lymphoma (GCB-DLBCL) and Burkitt ly

230 , namely follicular lymphoma (FL), GC B cell-diffuse large B cell lymphoma (GCB-DLBCL), and Burkitt l

231 ociated with the germinal center (GC) B-cell diffuse large B-cell lymphoma (GCB-DLBCL) subtype.

232 place of JAK2 inhibitors in the treatment of diffuse large B-cell lymphoma has not been defined; we s

233 e lymphomas, which occur in <10% of cases of diffuse large B-cell lymphoma, have been referred to as

234 Eligible histological subgroups included diffuse large B-cell lymphoma, high-grade B-cell lymphom

235 -cell lymphomas, including Burkitt lymphoma, diffuse large B-cell lymphoma, Hodgkin lymphoma, and pri

236 s to predict survival time for patients with diffuse large B-cell lymphoma, illustrate the behavior o

237 CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates of d

238 tion of patients with relapsed or refractory diffuse large B-cell lymphoma ineligible for autologous

239 The situation in diffuse large B-cell lymphoma is deceiving, as the possi

240 CT) as first-line treatment in patients with diffuse large B-cell lymphomas is still a matter of deba

241 40% among patients with follicular lymphoma, diffuse large B-cell lymphoma, mycosis fungoides, and pe

242 node biopsy samples, including FL (n = 20), diffuse large B-cell lymphoma (n = 10), classical Hodgki

243 rate was 69% across NHL subtypes and 55% for diffuse large B-cell lymphoma (n = 11); median response

244 s were treated (follicular lymphoma, n = 10; diffuse large B-cell lymphoma, n = 11; other B-cell lymp

245 with Hodgkin's lymphoma, Burkitt's lymphoma, diffuse large B-cell lymphomas, nasopharyngeal carcinoma

246 directed CAR (CTL019) to treat patients with diffuse large B-cell lymphoma or follicular lymphoma tha

247 Patients with diffuse large B-cell lymphoma or follicular lymphoma tha

248 B-cell malignancies of the following types: diffuse large B-cell lymphoma or primary mediastinal B-c

249 NK cells from both diffuse large B-cell lymphoma patients and Eu-myc B-cell

250 Lymphoma cells from diffuse large B-cell lymphoma patients had high basal ph

251 Neither DS nor risk stratification of diffuse large B-cell lymphoma patients is affected by th

252 ecently published RNA sequencing data on 234 diffuse large B-cell lymphoma patients, we found that hi

253 ditionally, ASO-based MDM4 targeting reduced diffuse large B cell lymphoma PDX growth.

254 Compared with HIV-associated diffuse large B-cell lymphoma, PEL was associated with s

255 1.29) and was significantly associated with diffuse large B cell lymphoma (pooled HR per SD: 1.47; 9

256 h bulky stage 2-3 or stage 3-4 CD20-positive diffuse large B-cell lymphoma, previously untreated, and

257 ly confirmed large B-cell lymphoma-including diffuse large B-cell lymphoma, primary mediastinal B-cel

258 phase 2 trial, we enrolled 111 patients with diffuse large B-cell lymphoma, primary mediastinal B-cel

259 66 patients with newly diagnosed diffuse large B-cell lymphoma received the polatuzumab v

260 res were also the key predictors of risk for diffuse large B-cell lymphoma (recent CD4 count <50 cell

261 me for elderly patients with newly diagnosed diffuse large B-cell lymphoma remains suboptimal in the

262 ents with various NHL histologies, including diffuse large B-cell lymphoma, Richter's transformation,

263 ggressive lymphomas, the association between diffuse large B-cell lymphoma risk and slope was restric

264 pecific aberrant chromatin conformation in a diffuse large B-cell lymphoma sample; and (4) the system

265 iminary clinical activity in newly diagnosed diffuse large B-cell lymphoma seems promising and encour

266 ed with the activated B cell-like subtype of diffuse large B cell lymphoma somehow perturb ID-mediate

267 y, oncogenic CARD11 variants associated with diffuse large B cell lymphoma spontaneously induce Lin(U

268 n lymphoma, primary effusion lymphoma, and a diffuse large B-cell lymphoma subgroup.

269 sisted of follicular lymphoma misgrading and diffuse large B-cell lymphoma subtype misclassification.

270 ed a new category of lymphoma, separate from diffuse large B-cell lymphoma, termed high-grade B-cell

271 She had a history of diffuse large B-cell lymphoma that had been diagnosed an

272 Patients with diffuse large B-cell lymphoma that is refractory to prim

273 ecially in cancers such as acute leukemia or diffuse large B-cell lymphoma that require rapid interve

274 on, which is impaired in approximately 6% of diffuse large B-cell lymphomas that carry inactivating g

275 ranged from eight (18%) of 45 patients with diffuse large B-cell lymphoma to 19 (53%) of 36 patients

276 This is the first large-scale study in diffuse large B-cell lymphoma to use real-time molecular

277 or both (double-hit or triple-hit lymphoma), diffuse large B-cell lymphoma transformed from any indol

278 Nineteen patients had diffuse large B-cell lymphoma, two patients had follicul

279 Current diagnostic tests for diffuse large B-cell lymphoma use the updated WHO criter

280 dgkin lymphoma and eight of 20 patients with diffuse large B-cell lymphoma vs one of 15 patients with

281 ing the risk of prostate cancer mortality or diffuse large B-cell lymphoma was limited.

282 Applying CIRI to patients with diffuse large B cell lymphoma, we demonstrate improved o

283 Overall, 126 patients with diffuse large B-cell lymphoma were included (56 female a

284 Patients with any stage of diffuse large B-cell lymphoma were treated with six cycl

285 elapsed/refractory NHL, who included 14 with diffuse large B-cell lymphoma, were enrolled; 42 receive

286 ore frequently mutated in PMBL compared with diffuse large B-cell lymphoma, whereas only a limited nu

287 oxorubicin, vincristine, and prednisone) for diffuse large B-cell lymphoma, which have not been assoc

288 T cell collection in a 65-year-old male with diffuse large B cell lymphoma who failed initial CAR T c

289 Patients with relapsed or refractory diffuse large B-cell lymphoma who are ineligible for aut

290 on after chemoimmunotherapy in patients with diffuse large B-cell lymphoma who are not candidates for

291 llow-up of 28.6 months, 86% of patients with diffuse large B-cell lymphoma who had a response (95% CI

292 Of the 42 patients with diffuse large B-cell lymphoma who received R-pina, 25 (6

293 In 66 patients with diffuse large B-cell lymphoma who received the recommend

294 mide in patients with relapsed or refractory diffuse large B-cell lymphoma who were ineligible for au

295 g adult patients with relapsed or refractory diffuse large B-cell lymphoma who were ineligible for or

296 than 18 years with histologically confirmed diffuse large B-cell lymphoma, who relapsed or had refra

297 to 50% of patients with Hodgkin lymphoma and diffuse large B-cell lymphoma will relapse, requiring ad

298 mab vedotin in patients with newly diagnosed diffuse large B-cell lymphoma with an International Prog

299 d evaluation of molecular guided therapy for diffuse large B-cell lymphoma with bortezomib (REMoDL-B)

300 eviously untreated, histologically confirmed diffuse large B-cell lymphoma with sufficient diagnostic